13.03.2024 13:05:28
|
PepGen Secures FDA's Orphan Drug, Rare Pediatric Disease Designations For PGN-EDO51
(RTTNews) - Wednesday, PepGen Inc. (PEPG) announced that PGN-EDO51, a potential therapeutic for Duchenne muscular dystrophy or DMD patients, has received orphan drug and rare pediatric disease designations from the FDA.
The company said that PGN-EDO51 is anticipated to be beneficial for patients with mutations suitable for the exon 51 skipping approach.
PepGen is presently assessing PGN-EDO51 in the CONNECT 1 Phase 2 trial and intends to commence patient enrollment in the CONNECT 2 Phase 2 trial later this year.
![](https://images.finanzen.at/images/unsortiert/wertpapierdepot-absichern-aktienchart-boerse-750493204-260.jpg)
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu PepGen Inc Registered Shsmehr Nachrichten
Keine Nachrichten verfügbar. |
Analysen zu PepGen Inc Registered Shsmehr Analysen
Aktien in diesem Artikel
PepGen Inc Registered Shs | 1,24 | -10,14% |
|